RESUMEN
The long-term prospective multi-centre nationwide (French) observational study FRANCISCO will provide new information on perimembranous ventricular septal defect with left ventricular overload but no pulmonary hypertension in children older than 1 year. Outcomes will be compared according to treatment strategy (watchful waiting, surgical closure, or percutaneous closure) and anatomic features of the defect. The results are expected to provide additional guidance about the optimal treatment of this specific population, which is unclear at present. BACKGROUND: The management of paediatric isolated perimembranous ventricular septal defect (pmVSD) with left ventricle (LV) volume overload but no pulmonary arterial hypertension (PAH) remains controversial. Three therapeutic approaches are considered: watchful waiting, surgical closure, and percutaneous closure. We aim to investigate the long-term outcomes of these patients according to anatomic pmVSD characteristics and treatment strategy. METHODS: The Filiale de Cardiologie Pediatrique et Congénitale (FCPC) designed the FRANCISCO registry, a long-term prospective nationwide multi-centre observational cohort study sponsored by the French Society of Cardiology, which enrolled, over 2 years (20182020), patients older than 1 year who had isolated pmVSD with LV volume overload. Prevalent complications related to pmVSD at baseline were exclusion criteria. Clinical, echocardiographic, and functional data will be collected at inclusion then after 1, 5, and 10 years. A core lab will analyse all baseline echocardiographic data to depict anatomical pmVSD features. The primary outcome is the 5-year incidence of cardiovascular events (infective endocarditis, sub-aortic stenosis, aortic regurgitation, right ventricular outflow tract stenosis, tricuspid regurgitation, PAH, arrhythmia, stroke, haemolysis, heart failure, or death from a cardiovascular event). We plan to enrol 200 patients, given the 10% estimated 5-year incidence of cardiovascular events with a 95% confidence interval of ±5%. Associations linking anatomical pmVSD features and treatment strategy to the incidence of complications will be assessed. CONCLUSIONS: The FRANSCICO study will provide the long-term incidence of complications in patients older than 1 year with pmVSD and LV volume overload. The results are expected to improve guidance for treatment decisions.
Asunto(s)
Insuficiencia Cardíaca , Defectos del Tabique Interventricular , Dispositivo Oclusor Septal , Cateterismo Cardíaco , Niño , Preescolar , Defectos del Tabique Interventricular/epidemiología , Defectos del Tabique Interventricular/cirugía , Ventrículos Cardíacos/diagnóstico por imagen , Humanos , Estudios Observacionales como Asunto , Estudios Prospectivos , Resultado del TratamientoRESUMEN
BACKGROUND: Although malaria remains one of the major public health threats in inter-tropical areas, there is limited understanding of imported malaria in children by paediatricians and emergency practitioners in non-endemic countries, often resulting in misdiagnosis and inadequate treatment. Moreover, classical treatments (atovaquone-proguanil, quinine, mefloquine) are limited either by lengthy treatment courses or by side effects. Since 2010, the World Health Organization (WHO) has recommended the use of oral artemisinin-based combination therapy for the treatment of uncomplicated Plasmodium falciparum malaria worldwide. The benefits of artenimol-piperaquine in children have been validated in endemic countries but experience remains limited in cases of imported malaria. METHODS: This prospective observational study in routine paediatric care took place at the Emergency Department, Robert-Debré Hospital (Paris, France) from September 2012 to December 2014. Tolerance and efficacy of artenimol-piperaquine in children presenting with the following inclusion criteria were assessed: P. falciparum positive on thin or thick blood smear; and the absence of WHO-defined features of severity. RESULTS: Among 83 children included in this study, treatment with artenimol-piperaquine was successful in 82 children (98.8%). None of the adverse events were severe and all were considered mild with no significant clinical impact. This also applied to cardiological adverse events despite a significant increase of the mean post-treatment QTc interval. CONCLUSION: Artenimol-piperaquine displays a satisfying efficacy and tolerance profile as a first-line treatment for children with imported uncomplicated falciparum malaria and only necessitates three once-daily oral intakes of the medication. Comparative studies versus artemether-lumefantrine or atovaquone-proguanil would be useful to confirm the results of this study.
Asunto(s)
Artemisininas/uso terapéutico , Enfermedades Transmisibles Importadas/tratamiento farmacológico , Malaria Falciparum/tratamiento farmacológico , Quinolinas/uso terapéutico , Adolescente , Niño , Preescolar , Enfermedades Transmisibles Importadas/parasitología , Quimioterapia Combinada , Servicio de Urgencia en Hospital , Femenino , Humanos , Lactante , Malaria Falciparum/diagnóstico , Masculino , Estudios Prospectivos , Resultado del TratamientoRESUMEN
Aims: To clarify the clinical characteristics and outcomes of children with SCN5A-mediated disease and to improve their risk stratification. Methods and results: A multicentre, international, retrospective cohort study was conducted in 25 tertiary hospitals in 13 countries between 1990 and 2015. All patients ≤16 years of age diagnosed with a genetically confirmed SCN5A mutation were included in the analysis. There was no restriction made based on their clinical diagnosis. A total of 442 children {55.7% boys, 40.3% probands, median age: 8.0 [interquartile range (IQR) 9.5] years} from 350 families were included; 67.9% were asymptomatic at diagnosis. Four main phenotypes were identified: isolated progressive cardiac conduction disorders (25.6%), overlap phenotype (15.6%), isolated long QT syndrome type 3 (10.6%), and isolated Brugada syndrome type 1 (1.8%); 44.3% had a negative electrocardiogram phenotype. During a median follow-up of 5.9 (IQR 5.9) years, 272 cardiac events (CEs) occurred in 139 (31.5%) patients. Patients whose mutation localized in the C-terminus had a lower risk. Compound genotype, both gain- and loss-of-function SCN5A mutation, age ≤1 year at diagnosis in probands and age ≤1 year at diagnosis in non-probands were independent predictors of CE. Conclusion: In this large paediatric cohort of SCN5A mutation-positive subjects, cardiac conduction disorders were the most prevalent phenotype; CEs occurred in about one-third of genotype-positive children, and several independent risk factors were identified, including age ≤1 year at diagnosis, compound mutation, and mutation with both gain- and loss-of-function.
Asunto(s)
Trastorno del Sistema de Conducción Cardíaco/genética , Estudios de Asociación Genética , Canal de Sodio Activado por Voltaje NAV1.5/genética , Factores de Edad , Enfermedades Asintomáticas , Síndrome de Brugada/genética , Niño , Preescolar , Electrocardiografía , Femenino , Estudios de Seguimiento , Mutación con Ganancia de Función , Humanos , Lactante , Recién Nacido , Síndrome de QT Prolongado/genética , Mutación con Pérdida de Función , Masculino , Estudios Retrospectivos , Factores de RiesgoRESUMEN
In order to assess cardiac tolerance of halofantrine in children, we studied, retrospectively, 15 non complicated falciparum malaria cases treated with halofantrine, and focused on the effect on ventricular repolarisation. Our data showed that halofantrine can produce a moderate QTc prolongation without any life-threatening arrhythmia. As long as contraindications of the drug are respected, this treatment should be considered as a therapeutical option in young children presenting with non complicated falciparum malaria.
Asunto(s)
Antimaláricos/efectos adversos , Electrofisiología Cardíaca , Fenómenos Electrofisiológicos/efectos de los fármacos , Síndrome de QT Prolongado/inducido químicamente , Fenantrenos/efectos adversos , Adolescente , Antimaláricos/administración & dosificación , Niño , Preescolar , Femenino , Humanos , Lactante , Malaria Falciparum/tratamiento farmacológico , Masculino , Fenantrenos/administración & dosificaciónRESUMEN
AIMS: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmic disorder with a highly malignant clinical course. Exercise-stress test is the first-line approach to diagnose suspected individuals. We sought to elucidate the value of exercise-stress test for predicting mutations and future cardiac events in CPVT-family relatives. METHODS AND RESULTS: The present study included 67 asymptomatic relatives (24 ± 15 years) of 17 genetically positive CPVT probands, who underwent exercise-stress test without any medication and genetic testing. Exercise-stress test, which was considered positive with the induction of ventricular tachycardia or premature ventricular contractions consisting of bigeminy or couplets, was positive in 17 relatives (25%). Genetic analysis disclosed mutations in 16 of these 17 relatives (94%) and in 16 of the 50 relatives (32%) with negative exercise-stress test; the sensitivity and specificity for a positive genotype were 50 and 97%, respectively (P< 0.001). Among 32 mutation carriers, cardiac events occurred in 7 of the 16 relatives with positive and 2 of the 16 relatives with negative exercise-stress test during the follow-up period of 9.6 ± 3.8 years, and four with positive and two with negative stress test were not on regular beta-blocker treatment at these events. In the 16 relatives with positive stress test, those on beta-blocker treatment demonstrated a trend of lower cardiac event rate (Log-rank P= 0.054). CONCLUSION: In asymptomatic relatives of CPVT probands, exercise-stress test can be used as a simple diagnostic tool. Nevertheless, because of the low sensitivity for predicting mutations and future cardiac events in those with negative stress test, genetic analysis should be performed to improve patient management.
Asunto(s)
Prueba de Esfuerzo/métodos , Mutación , Taquicardia Ventricular/genética , Adolescente , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Niño , Muerte Súbita Cardíaca/prevención & control , Electrocardiografía , Femenino , Frecuencia Cardíaca/efectos de los fármacos , Frecuencia Cardíaca/genética , Humanos , Masculino , Síncope/tratamiento farmacológico , Síncope/genética , Taquicardia Ventricular/tratamiento farmacológico , Complejos Prematuros Ventriculares/tratamiento farmacológico , Complejos Prematuros Ventriculares/genética , Adulto JovenRESUMEN
BACKGROUND: Loss-of-function mutations in the gene KCNQ1 encoding the Kv7.1 K(+) channel cause long QT syndrome type 1 (LQT1), whereas gain-of-function mutations are associated with short QT syndrome as well as familial atrial fibrillation (FAF). However, KCNQ1 mutation pleiotropy, which is capable of expressing both LQT1 and FAF, has not been demonstrated for a discrete KCNQ1 mutation. The genotype-phenotype relationship for a family with FAF suggests a possible association with the LQT1 p.Arg231Cys-KCNQ1 (R231C-Q1) mutation. OBJECTIVE: The purpose of this study was to determine whether R231C-Q1 also can be linked to FAF. METHODS: The R231C-Q1 proband with AF underwent genetic testing for possible mutations in 10 other AF-linked genes plus KCNH2 and SCN5A. Sixteen members from five other R231C-positive LQT1 families were genetically tested for 21 single nucleotide polymorphisms (SNPs) to determine if the FAF family had discriminatory SNPs associated with AF. R231C-Q1 was expressed with KCNE1 (E1) in HEK293 cells, and Q1E1 currents (I(Q1E1)) were analyzed using the whole-cell patch-clamp technique. RESULTS: Genetic analyses revealed no additional mutations or discriminatory SNPs. Cells expressing WT-Q1 and R231C-Q1 exhibited some constitutively active I(Q1E1) and smaller maximal I(Q1E1) compared to cells expressing WT-Q1. CONCLUSION: Constitutively active I(Q1E1) and a smaller peak I(Q1E1) are common features of FAF-associated and LQT1-associated mutations, respectively. These data suggest that the mixed functional properties of R231C-Q1 may predispose some families to LQT1 or FAF. We conclude that R231C is a pleiotropic missense mutation capable of LQT1 expression, AF expression, or both.
Asunto(s)
Pleiotropía Genética/genética , Predisposición Genética a la Enfermedad/genética , Canal de Potasio KCNQ1/genética , Mutación Missense , Síndrome de Romano-Ward/genética , Adulto , Fibrilación Atrial/genética , Biología Computacional , Femenino , Humanos , Masculino , Técnicas de Placa-Clamp , Linaje , Fenotipo , Polimorfismo de Nucleótido SimpleRESUMEN
BACKGROUND: The pathophysiological background of catecholaminergic polymorphic ventricular tachycardia is well understood, but the clinical features of this stress-induced arrhythmic disorder, especially the incidence and risk factors of arrhythmic events, have not been fully ascertained. METHODS AND RESULTS: The outcome in 101 catecholaminergic polymorphic ventricular tachycardia patients, including 50 probands, was analyzed. During a mean follow-up of 7.9 years, cardiac events defined as syncope, aborted cardiac arrest, including appropriate discharges from implantable defibrillators, or sudden cardiac death occurred in 27 patients, including 2 mutation carriers with normal exercise tests. The estimated 8-year event rate was 32% in the total population and 27% and 58% in the patients with and without beta-blockers, respectively. Absence of beta-blockers (hazard ratio [HR], 5.48; 95% CI, 1.80 to 16.68) and younger age at diagnosis (HR, 0.54 per decade; 95% CI, 0.33 to 0.89) were independent predictors. Fatal or near-fatal events defined as aborted cardiac arrest or sudden cardiac death occurred in 13 patients, resulting in an estimated 8-year event rate of 13%. Absence of beta-blockers (HR, 5.54; 95% CI, 1.17 to 26.15) and history of aborted cardiac arrest (HR, 13.01; 95% CI, 2.48 to 68.21) were independent predictors. No difference was observed in cardiac and fatal or near-fatal event rates between probands and family members. CONCLUSIONS: Cardiac and fatal or near-fatal events were not rare in both catecholaminergic polymorphic ventricular tachycardia probands and affected family members during the long-term follow-up, even while taking beta-blockers, which was associated with a lower event rate. Further studies evaluating concomitant therapies are necessary to improve outcome in these patients.
Asunto(s)
Calsecuestrina/genética , Polimorfismo Genético , Canal Liberador de Calcio Receptor de Rianodina/genética , Taquicardia Ventricular/genética , Taquicardia Ventricular/mortalidad , Adolescente , Antagonistas Adrenérgicos beta/uso terapéutico , Adulto , Niño , Preescolar , Muerte Súbita Cardíaca/epidemiología , Prueba de Esfuerzo , Salud de la Familia , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Estimación de Kaplan-Meier , Masculino , Persona de Mediana Edad , Factores de Riesgo , Síncope/genética , Síncope/mortalidad , Taquicardia Ventricular/prevención & control , Adulto JovenRESUMEN
BACKGROUND: Beta-blocker efficacy in long-QT syndrome type 1 is good but variably reported, and the causes of cardiac events despite beta-blocker therapy have not been ascertained. METHODS AND RESULTS: This was a retrospective study of the details surrounding cardiac events in 216 genotyped long-QT syndrome type 1 patients treated with beta-blocker and followed up for a median time of 10 years. Before beta-blocker, cardiac events occurred in 157 patients (73%) at a median age of 9 years, with cardiac arrest (CA) in 26 (12%). QT-prolonging drugs were used by 17 patients; 9 of 17 (53%) had CA compared with 17 of 199 nonusers (8.5%; odds ratio, 12.0; 95% confidence interval, 4.1 to 35.3; P<0.001). After beta-blocker, 75% were asymptomatic, and cardiac events were significantly reduced (P<0.001), with a median event count (quartile 1 to 3) per person of 0 (0 to 1). Twelve patients (5.5%) suffered CA/sudden death, but 11 of 12 (92%) were noncompliant (n=8), were on a QT-prolonging drug (n=2), or both (n=1) at the time of the event. The risk for CA/sudden death in compliant patients not taking QT-prolonging drugs was dramatically less compared with noncompliant patients on QT-prolonging drugs (odds ratio, 0.03; 95% confidence interval, 0.003 to 0.22; P=0.001). None of the 26 patients with CA before beta-blocker had CA/sudden death on beta-blockers. CONCLUSIONS: beta-Blockers are extremely effective in long-QT syndrome type 1 and should be administered at diagnosis and ideally before the preteen years. beta-Blocker noncompliance and use of QT-prolonging drug are responsible for almost all life-threatening "beta-blocker failures." beta-Blockers are appropriate therapy for asymptomatic patients and those who have never had a CA or beta-blocker therapy. Routine implantation of cardiac defibrillators in such patients does not appear justified.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Efectos Colaterales y Reacciones Adversas Relacionados con Medicamentos , Cooperación del Paciente , Síndrome de Romano-Ward/tratamiento farmacológico , Adolescente , Antagonistas Adrenérgicos beta/farmacocinética , Adulto , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Mutación/genética , Preparaciones Farmacéuticas/metabolismo , Estudios Retrospectivos , Síndrome de Romano-Ward/genética , Síndrome de Romano-Ward/mortalidad , Insuficiencia del Tratamiento , Adulto JovenRESUMEN
Brugada syndrome is characterized clinically by the onset of syncopes or sudden death related to ventricular tachyarrhythmias in patients with a structurally normal heart. Its electrocardiographic features include right bundle branch bloc and ST-segment elevations in the precordial leads V1-V3. The estimated prevalence is 1 per 1000 in Asian countries and probably lower elsewhere: Asia is probably a birthplace of the syndrome. Its transmission is autosomal dominant with variable penetrance. Mutations have been identified in a gene coding for the alpha subunit of the sodium channel (SCN5A) in only 25% of cases. These genetic abnormalities cause a reduction of the density of the sodium current and explain the aggravation of electrocardiographic abnormalities caused by antiarrhythmic sodium channel blockers. Prognosis is very serious in symptomatic patients: prevention of sudden death requires implantation of an automatic defibrillator. The treatment decision is much more difficult for asymptomatic subjects with no family history.
Asunto(s)
Síndrome de Brugada , Algoritmos , Antiarrítmicos , Asia/epidemiología , Síndrome de Brugada/diagnóstico , Síndrome de Brugada/epidemiología , Síndrome de Brugada/genética , Síndrome de Brugada/terapia , Bloqueo de Rama/etiología , Contraindicaciones , Muerte Súbita Cardíaca/etiología , Árboles de Decisión , Desfibriladores Implantables , Electrocardiografía , Francia/epidemiología , Genes Dominantes/genética , Asesoramiento Genético , Pruebas Genéticas , Humanos , Proteínas Musculares/genética , Mutación/genética , Canal de Sodio Activado por Voltaje NAV1.5 , Penetrancia , Prevalencia , Pronóstico , Psicotrópicos , Medición de Riesgo , Canales de Sodio/genética , Síncope/etiología , Taquicardia Ventricular/etiologíaRESUMEN
BACKGROUND: Brugada syndrome is an arrhythmogenic disease characterized by an ECG pattern of ST-segment elevation in the right precordial leads and augmented risk of sudden cardiac death. Little is known about the clinical presentation and prognosis of this disease in children. METHODS AND RESULTS: Thirty children affected by Brugada syndrome who were <16 years of age (mean, 8+/-4 years) were included. All patients displayed a type I ECG pattern before or after drug provocation challenge. Diagnosis of Brugada syndrome was made under the following circumstances: aborted sudden death (n=1), syncope of unexplained origin (n=10), symptomatic supraventricular tachycardia (n=1), suspicious ECG (n=1), and family screening for Brugada syndrome (n=17). Syncope was precipitated by fever in 5 cases. Ten of 11 symptomatic patients displayed a spontaneous type I ECG. An implantable cardioverter-defibrillator was implanted in 5 children; 4 children were treated with hydroquinidine; and 1 child received a pacemaker because of symptomatic sick sinus syndrome. During a mean follow-up of 37+/-23 months, 1 child experienced sudden cardiac death, and 2 children received an appropriate implantable cardioverter-defibrillator shock; all of them were symptomatic and had manifested a type I ECG spontaneously. One child had a cardioverter-defibrillator infection that required explantation of the defibrillator. CONCLUSIONS: In the largest population of children affected by Brugada syndrome described to date, fever represented the most important precipitating factor for arrhythmic events, and as in the adult population, the risk of arrhythmic events was higher in previously symptomatic patients and in those displaying a spontaneous type I ECG.
Asunto(s)
Síndrome de Brugada/diagnóstico , Adolescente , Antiarrítmicos/uso terapéutico , Síndrome de Brugada/complicaciones , Síndrome de Brugada/fisiopatología , Niño , Preescolar , Muerte Súbita Cardíaca/etiología , Desfibriladores Implantables , Electrocardiografía , Femenino , Estudios de Seguimiento , Genes Dominantes , Humanos , Lactante , Masculino , Proteínas Musculares/genética , Canal de Sodio Activado por Voltaje NAV1.5 , Pronóstico , Quinidina/uso terapéutico , Bloqueadores de los Canales de Sodio , Canales de Sodio/genética , Síncope/etiología , Taquicardia Supraventricular/diagnóstico , Taquicardia Supraventricular/etiologíaRESUMEN
Aortic root dilatation is the principal life-threatening complication in Marfan syndrome, leading to aortic regurgitation, dissection, and rupture. Beta blockade slows aortic dilatation in adults, but there has been no definitive evidence in children. Therefore, the evolution of aortic diameter at the level of the sinuses of Valsalva in 155 children (82 males, 73 females) aged <12 years who had been diagnosed with Marfan syndrome according to international criteria was retrospectively studied. Affected children treated by beta blockade >or=1 time during their lives (n = 77, mean age at diagnosis 6.1 +/- 3.2 years) were compared with affected children who had never received beta blockers (n = 78; 42 males, mean age 7.4 +/- 5.2 years). A mean delay of 1.3 years was observed between diagnosis and the initiation of beta blockade in the treated group (mean age at initiation 7.5 years). At the time of diagnosis, aortic diameters were similar in the 2 groups, but after 1.3 years, aortic diameters were greater in the group of children in whom beta blockers had been initiated. On univariate analysis, aortic diameter was related to age and height, but not gender or familial history of aortic dissection. On multivariate analysis, treatment and age remained significant determinants of aortic diameter. Beta blockade significantly decreased the rate of aortic dilatation at the level of the sinuses of Valsalva by a mean of 0.16 mm/year (p <0.05), an effect that increased with treatment duration. A trend toward lower cardiac mortality, decreased need for preventive aortic surgery, and less dissection was observed. In conclusion, beta blockade appears to limit aortic dilatation during childhood in patients affected by Marfan syndrome. Therefore, this treatment should be recommended as soon as the diagnosis is made.
Asunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Enfermedades de la Aorta/tratamiento farmacológico , Síndrome de Marfan/complicaciones , Seno Aórtico , Enfermedades de la Aorta/etiología , Niño , Dilatación Patológica/diagnóstico por imagen , Dilatación Patológica/tratamiento farmacológico , Dilatación Patológica/etiología , Ecocardiografía , Femenino , Estudios de Seguimiento , Humanos , Masculino , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Resultado del TratamientoAsunto(s)
Antagonistas Adrenérgicos beta/uso terapéutico , Aneurisma de la Aorta/prevención & control , Disección Aórtica/prevención & control , Síndrome de Marfan/tratamiento farmacológico , Antagonistas Adrenérgicos beta/efectos adversos , Atenolol/uso terapéutico , Bisoprolol/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Quimioterapia Combinada , Francia , Humanos , Síndrome de Marfan/diagnóstico , Sociedades Médicas , Resultado del Tratamiento , Verapamilo/uso terapéuticoRESUMEN
BACKGROUND: When the left ventricle is unable to sustain a systemic pressure in transposition of the great arteries (TGA), left ventricular retraining is mandatory before the morphologic left ventricle under the aorta is switched. This is currently achieved by creating a ventricular overload through pulmonary artery banding, usually associated with an aortopulmonary shunt in case of a TGA with an intact ventricular septum. Our experimental study compared three different modes of increased ventricular afterload to obtain ventricular hypertrophy. METHODS: Fifteen lambs (mean weight 48 kg) underwent pulmonary artery banding. Five animals (group I) received a classic band; 5 (group II) received a classic band which was adjusted at week 1 and 3; and 4 (group III) received a band which was tightened for 1 hour, twice a day (early morning and late afternoon). After 5 weeks, the lambs were evaluated hemodynamically before they were sacrificed and their hearts harvested for histologic examination. RESULTS: No difference was noted in the hemodynamic data between groups 1 and II. Group III showed a greater ability to increase ventricular pressure in this model. No significant difference was noted between the three groups in terms of macroscopic alterations, but all animals demonstrated an increase in right ventricular wall thickness compared with control animals. Several fibrosis areas were evident in group I and II but none in group III. CONCLUSIONS: Intermittent pulmonary artery banding is able to induce hemodynamically sufficient ventricular hypertrophy without fibrosis.
Asunto(s)
Ventrículos Cardíacos/fisiopatología , Cuidados Preoperatorios/métodos , Arteria Pulmonar , Transposición de los Grandes Vasos/cirugía , Animales , Insuficiencia de la Válvula Aórtica/etiología , Constricción , Fibrosis , Tabiques Cardíacos/patología , Hemodinámica , Hemorreología , Hipertrofia Ventricular Izquierda/etiología , Métodos , Miocardio/patología , Ovinos , Método Simple CiegoRESUMEN
A 31-year-old man with uncorrected aortopulmonary window and fixed pulmonary hypertension experienced dissection of the pulmonary artery, rapidly complicated by a fatal spontaneous rupture into the pericardium. In the setting of pulmonary hypertension, the diagnosis of dissection and rupture of the pulmonary artery should be considered in cases of thoracic pain or cardiogenic shock.
Asunto(s)
Aneurisma Roto/etiología , Aorta/anomalías , Disección Aórtica/etiología , Muerte Súbita Cardíaca/etiología , Hipertensión Pulmonar/complicaciones , Arteria Pulmonar/anomalías , Adulto , Disección Aórtica/diagnóstico por imagen , Disección Aórtica/cirugía , Aneurisma Roto/cirugía , Aorta/diagnóstico por imagen , Válvula Aórtica/diagnóstico por imagen , Aortografía , Dolor en el Pecho/etiología , Resultado Fatal , Humanos , Complicaciones Intraoperatorias , Masculino , Inutilidad Médica , Arteria Pulmonar/diagnóstico por imagen , Válvula Pulmonar/diagnóstico por imagen , Rotura Espontánea , Choque Cardiogénico/etiología , Tomografía Computarizada Espiral , UltrasonografíaRESUMEN
OBJECTIVE: Aside from congenital heart block (CHB), sinus bradycardia and prolongation of the corrected QT (QTc) interval have been reported in infants born to mothers with anti-SSA antibodies. To assess the pathologic nature of these manifestations, this study focused on electrocardiographic (EKG) variations in these children, comparing them with findings in a control group. METHODS: We studied 165 consecutive pregnancies in 106 anti-SSA-positive women with connective tissue diseases (CTDs). EKGs obtained on 58 children of this group were compared with those obtained on 85 infants born to mothers with CTD who were negative for both anti-SSA and anti-SSB. RESULTS: No statistically significant difference was seen between the 2 study groups with regard to gestational age, prematurity, birth weight, age of the children at the time of EKG, age of the mothers, or treatments received by the mothers during their pregnancies. Seven of 137 children developed cutaneous neonatal lupus syndrome; 1 child developed CHB (CHB risk of 1 in 99 [1%] if only the first prospectively observed pregnancy in women without a history of CHB is included in the analysis). For EKGs recorded during the first 2 months of life, the mean +/- SD PR interval was 96 +/- 16 msec in the anti-SSA-positive group and 96 +/- 13 msec in the anti-SSA-negative group (P = 0.84), with mean QTc values of 397 +/- 27 and 395 +/- 25 msec (P = 0.57) and mean heart rates of 141 +/- 23 and 137 +/- 21 beats per minute (P = 0.20), respectively. No difference in the PR interval, QTc interval, or heart rate was observed for EKGs obtained between 2 and 4 months of life. When EKGs obtained at 0-2 months were compared with those obtained at 2-4 months, a physiologic prolongation of the QTc interval was observed in both study groups. No sudden infant death or symptomatic arrhythmia occurred during the first year of life. CONCLUSION: The EKG findings in children of anti-SSA-positive and anti-SSA-negative mothers were not significantly different. Our results suggest that the prolongation of the QTc interval and sinus bradycardia that have recently been reported in children of mothers with anti-SSA antibodies occur independently of the anti-SSA antibodies. The pathologic nature of these EKG variations was not confirmed by our controlled study.
Asunto(s)
Anticuerpos Antinucleares/sangre , Enfermedades del Tejido Conjuntivo , Electrocardiografía , Complicaciones del Embarazo , Resultado del Embarazo , Adulto , Bradicardia/etiología , Anomalías Congénitas , Femenino , Frecuencia Cardíaca , Humanos , Recién Nacido , Lupus Eritematoso Cutáneo/congénito , Masculino , EmbarazoRESUMEN
OBJECTIVES: We hypothesized that neonatal long QT syndrome (LQTS) with 2:1 atrioventricular block (AVB) could be related to HERG mutations. BACKGROUND: Early onset of LQTS is rare but carries a high risk of life-threatening events such as ventricular arrhythmias and conduction disorders. There are no data on possible gene specificity. METHODS: We analyzed the characteristics and outcomes of 23 neonate probands from our LQTS population. Samples of DNA were available in 18 cases. RESULTS: Long QT syndrome was diagnosed because of corrected QT interval (QTc) prolongation (mean QTc of 558 +/- 62 ms) and neonatal bradycardia attributable to sinus bradycardia (n = 8) or 2:1 AVB (n = 15). Symptoms included syncope (n = 2), torsades de pointes (n = 7), and hemodynamic failure (n = 6). Three infants with 2:1 AVB died during the first month of life. During the neonatal period, all living patients received beta-blockers (BB) and 13 had a combination of BB and permanent cardiac pacing. Under treatment, patients remained asymptomatic, with a mean follow-up of seven years. Mutations were identified in HERG (n = 8) and KCNQ1 (n = 8), and one child had three mutations (HERG, KCNQ1, and SCN5A). Conduction disorders were associated with LQT2, whereas sinus bradycardia was associated with LQT1. CONCLUSIONS: Two-to-one AVB seems preferentially associated with HERG mutations, either isolated or combined. Long QT syndrome with relative bradycardia attributable to 2:1 AVB has a poor prognosis during the first month of life. In contrast, sinus bradycardia seems to be associated with KCNQ1 mutations, with a good short-term prognosis under BB therapy.
Asunto(s)
Bradicardia/genética , Proteínas de Transporte de Catión/genética , Síndrome de QT Prolongado/genética , Mutación , Canales de Potasio con Entrada de Voltaje , Canales de Potasio/genética , Canales de Potasio Éter-A-Go-Go , Femenino , Estudios de Seguimiento , Humanos , Recién Nacido , Canales de Potasio KCNQ , Canal de Potasio KCNQ1 , MasculinoRESUMEN
OBJECTIVE: The use of hydroxychloroquine (HCQ) in pregnancy remains controversial. The recent demonstration that HCQ passes across the placenta, with cord blood concentrations nearly identical to those found in maternal blood, emphasizes the need for careful evaluation of pregnancies in women receiving HCQ. However, only small series of HCQ-treated pregnant women have been reported, and most of these studies had no control group. We now report our experience with 133 pregnancies in women being treated with HCQ, resulting in 117 live births. Results in the HCQ group are compared with those in a control group. METHODS: One hundred thirty-three consecutive pregnancies in 90 women treated with 200 mg of HCQ either twice daily (122 pregnancies) or once daily (11 pregnancies) were studied. These pregnancies were compared with 70 consecutive pregnancies in 53 women with similar disorders who did not receive HCQ. Electrocardiography was performed in 47 children of mothers treated with HCQ and in 45 children in the control group. RESULTS: Eighty-eight percent of pregnancies in the HCQ group and 84% of those in the control group ended successfully with a live birth. The outcomes of pregnancy were not statistically different between groups. One child in each group died of causes related to prematurity. Three malformations were observed in the HCQ group (1 hypospadias, 1 craniostenosis, and 1 cardiac malformation) versus 4 in the control group. On the electrocardiograms, the PR interval and the corrected QT interval were not statistically different between groups. No visual, hearing, growth, or developmental abnormalities were reported in any of the children at the last follow-up (ages 12-108 months; mean age 26 months). CONCLUSION: Our findings support preliminary evidence for the safety of HCQ therapy during pregnancy. This treatment probably should be maintained throughout pregnancy in patients with systemic lupus erythematosus.
Asunto(s)
Antirreumáticos/uso terapéutico , Hidroxicloroquina/uso terapéutico , Lupus Eritematoso Sistémico/tratamiento farmacológico , Complicaciones del Embarazo , Antirreumáticos/farmacocinética , Peso al Nacer/efectos de los fármacos , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Hidroxicloroquina/farmacocinética , Lactante , Recién Nacido , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/metabolismo , Edad Materna , Exposición Materna , Intercambio Materno-Fetal , Embarazo , Resultado del Embarazo , Embarazo de Alto Riesgo , Efectos Tardíos de la Exposición PrenatalRESUMEN
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a rare arrhythmogenic disorder characterized by syncopal events and sudden cardiac death at a young age during physical stress or emotion, in the absence of structural heart disease. We report the first nonsense mutations in the cardiac calsequestrin gene, CASQ2, in three CPVT families. The three mutations, a nonsense R33X, a splicing 532+1 G>A, and a 1-bp deletion, 62delA, are thought to induce premature stop codons. Two patients who experienced syncopes before the age of 7 years were homozygous carriers, suggesting a complete absence of calsequestrin 2. One patient was heterozygous for the stop codon and experienced syncopes from the age of 11 years. Despite the different mutations, there is little phenotypic variation of CPVT for the CASQ2 mutations. Of the 16 heterozygous carriers of these various mutations, 14 were devoid of clinical symptoms or ECG anomalies, whereas 2 of them had ventricular arrhythmias at ECG on exercise tests. In line with this, the diagnosis of the probands was difficult because of the absence of a positive family history. In conclusion, these additional three CASQ2 CPVT families suggest that CASQ2 mutations are more common than previously thought and produce a severe form of CPVT. The full text of this article is available at http://www.circresaha.org.